OBLN vs. NSPR, CTCX, TMDIF, HSAQ, GBS, PETV, RVP, BTCY, INVO, and NAYA
Should you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include InspireMD (NSPR), Carmell (CTCX), Titan Medical (TMDIF), Health Sciences Acquisitions Co. 2 (HSAQ), GBS (GBS), PetVivo (PETV), Retractable Technologies (RVP), Biotricity (BTCY), INVO Bioscience (INVO), and NAYA Biosciences (NAYA). These companies are all part of the "medical" sector.
Obalon Therapeutics vs. Its Competitors
InspireMD (NYSE:NSPR) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.
Obalon Therapeutics has lower revenue, but higher earnings than InspireMD.
In the previous week, InspireMD had 8 more articles in the media than Obalon Therapeutics. MarketBeat recorded 8 mentions for InspireMD and 0 mentions for Obalon Therapeutics. InspireMD's average media sentiment score of 1.18 beat Obalon Therapeutics' score of 0.00 indicating that InspireMD is being referred to more favorably in the media.
InspireMD has a net margin of -413.96% compared to Obalon Therapeutics' net margin of -776.76%. InspireMD's return on equity of -69.42% beat Obalon Therapeutics' return on equity.
44.8% of InspireMD shares are owned by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are owned by institutional investors. 34.1% of InspireMD shares are owned by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
InspireMD has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500.
InspireMD presently has a consensus target price of $4.50, suggesting a potential upside of 67.29%. Given InspireMD's stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than Obalon Therapeutics.
Summary
InspireMD beats Obalon Therapeutics on 12 of the 15 factors compared between the two stocks.
Get Obalon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Obalon Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:OBLN) was last updated on 8/2/2025 by MarketBeat.com Staff
